TransCode completes Phase 1a of TTX-MC138; 44% stable disease rate, moves to Phase 2a

Transcode Therapeutics, Inc.

16 patients treated across 4 dose levels; no dose-limiting toxicities or significant safety events observed.
Median treatment duration of 4 months (range 2–12); three patients remain on trial.
44% (7/16) achieved stable disease lasting ≥4 months per RECIST; one thyroid cancer patient had undetectable thyroglobulin.
Recommended Phase 2 dose established; company plans to initiate Phase 2a efficacy trial.
PK profile shows predictable exposure; pharmacodynamic effects consistent with preclinical models and prior Phase 0.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.